Launched in 2014, Lynparza has already shown success treating later stage breast cancer, which has spread and cannot be cured, and ovarian and pancreatic cancer. “This is a completely new way of using cancer genetics in the curative setting,” he said. “OlympiA’s findings highlight the need for genetic testing for BRCA mutations in patients diagnosed with high-risk early-stage breast cancer,” she said. Amgen will share survival data from its cancer drug Lumakras targeting KRAS - previously known as the “undruggable target” - an oncogene master switch that made cells cancerous. Recently, the drug received Food and Drug Administration approval for patients with non-small cell lung cancer with a specific genetic mutation.

Source: The Irish Times June 04, 2021 04:41 UTC